Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 2.49
AVEO's Cash to Debt is ranked lower than
69% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. AVEO: 2.49 )
Ranked among companies with meaningful Cash to Debt only.
AVEO' s Cash to Debt Range Over the Past 10 Years
Min: 1.54  Med: 5.99 Max: N/A
Current: 2.49
Equity to Asset 0.32
AVEO's Equity to Asset is ranked lower than
83% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. AVEO: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
AVEO' s Equity to Asset Range Over the Past 10 Years
Min: -3.21  Med: 0.48 Max: 0.79
Current: 0.32
-3.21
0.79
F-Score: 3
Z-Score: -20.76
M-Score: 2.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -47.33
AVEO's Operating margin (%) is ranked higher than
56% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. AVEO: -47.33 )
Ranked among companies with meaningful Operating margin (%) only.
AVEO' s Operating margin (%) Range Over the Past 10 Years
Min: -8035.89  Med: -198.82 Max: 20.59
Current: -47.33
-8035.89
20.59
Net-margin (%) -58.93
AVEO's Net-margin (%) is ranked higher than
54% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. AVEO: -58.93 )
Ranked among companies with meaningful Net-margin (%) only.
AVEO' s Net-margin (%) Range Over the Past 10 Years
Min: -8277.57  Med: -212.81 Max: 18.59
Current: -58.93
-8277.57
18.59
ROE (%) -77.04
AVEO's ROE (%) is ranked lower than
75% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. AVEO: -77.04 )
Ranked among companies with meaningful ROE (%) only.
AVEO' s ROE (%) Range Over the Past 10 Years
Min: -116.49  Med: -79.30 Max: 20.76
Current: -77.04
-116.49
20.76
ROA (%) -29.74
AVEO's ROA (%) is ranked lower than
52% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. AVEO: -29.74 )
Ranked among companies with meaningful ROA (%) only.
AVEO' s ROA (%) Range Over the Past 10 Years
Min: -88.25  Med: -48.61 Max: 13.74
Current: -29.74
-88.25
13.74
ROC (Joel Greenblatt) (%) -804.78
AVEO's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. AVEO: -804.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AVEO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1269.33  Med: -769.44 Max: 689.47
Current: -804.78
-1269.33
689.47
Revenue Growth (3Y)(%) -8.40
AVEO's Revenue Growth (3Y)(%) is ranked lower than
65% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. AVEO: -8.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AVEO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -65.65 Max: -8.4
Current: -8.4
EBITDA Growth (3Y)(%) -71.80
AVEO's EBITDA Growth (3Y)(%) is ranked lower than
98% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. AVEO: -71.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AVEO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -71.80 Max: 7.2
Current: -71.8
0
7.2
EPS Growth (3Y)(%) -53.30
AVEO's EPS Growth (3Y)(%) is ranked lower than
92% of the 492 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. AVEO: -53.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AVEO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -53.30 Max: 5.7
Current: -53.3
0
5.7
» AVEO's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-10)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AVEO Guru Trades in Q2 2015

Jim Simons 2,120,800 sh (+66.21%)
Paul Tudor Jones 82,292 sh (-6.72%)
» More
Q3 2015

AVEO Guru Trades in Q3 2015

Paul Tudor Jones 83,869 sh (+1.92%)
Jim Simons 2,091,800 sh (-1.37%)
» More
Q4 2015

AVEO Guru Trades in Q4 2015

Paul Tudor Jones 83,869 sh (unchged)
Jim Simons 1,975,900 sh (-5.54%)
» More
Q1 2016

AVEO Guru Trades in Q1 2016

Jim Simons 2,094,900 sh (+6.02%)
Paul Tudor Jones 83,869 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AVEO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CALA, NAS:OCRX, NAS:TCON, NAS:DNAI, AMEX:XXII, NAS:NVET, AMEX:CVM, OTCPK:DYAI, AMEX:IBIO, OTCPK:HPPI, OTCPK:OGRMF, NAS:ALDX, NAS:AGLE, AMEX:CRMD, NAS:TTHI, NAS:PBMD, AMEX:RNN, AMEX:PLX, NAS:CATB, NAS:KMPH » details
Traded in other countries:VPA.Germany,
AVEO Pharmaceuticals Inc is a biopharmaceutical company. It is involved in discovering, developing and commercializing novel cancer therapeutics.

AVEO Pharmaceuticals Inc was incorporated under the laws of the State of Delaware on October 19, 2001 as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. on March 1, 2005. The Company is a cancer therapeutics company that discovers, develops and commercializes targeted cancer therapies to impact patients' lives. The Company's proprietary Human Response Platform provides the company insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. Its product under development include: AV-203, an anti-ErbB3 monoclonal antibody with broad therapeutic potential. Ficlatuzumab, is a Hepatocyte Growth Factor, or HGF, inhibitory antibody. Tivozanib, is an investigational tyrosine kinase inhibitor of all three vascular endothelial growth factor, or VEGF receptors. AV-380, a potential first-in-class GDF-15 inhibitor, was discovered using proprietary Human Response Platform, that provides the company insights into cancer and related disease biology. The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc. and GlaxoSmithKline plc. The Company contracts with third parties for the manufacture of clinical product candidates. On March 9, 2014, Company entered into a manufacturing agreement with AbbVie Inc. for the process and development of AV-380. In August 2010, it entered into an agreement with Gallus BioPharmaceuticals, LLC for the clinical manufacture of AV-203 drug substance. The Company seeks trademark protection in the U.S. and foreign jurisdictions where available and when appropriate.

Ratios

vs
industry
vs
history
P/B 5.87
AVEO's P/B is ranked lower than
70% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. AVEO: 5.87 )
Ranked among companies with meaningful P/B only.
AVEO' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 2.93 Max: 22.25
Current: 5.87
0.87
22.25
P/S 2.82
AVEO's P/S is ranked higher than
83% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. AVEO: 2.82 )
Ranked among companies with meaningful P/S only.
AVEO' s P/S Range Over the Past 10 Years
Min: 0.88  Med: 4.54 Max: 101.25
Current: 2.82
0.88
101.25
EV-to-EBIT -4.50
AVEO's EV-to-EBIT is ranked lower than
99.99% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. AVEO: -4.50 )
Ranked among companies with meaningful EV-to-EBIT only.
AVEO' s EV-to-EBIT Range Over the Past 10 Years
Min: -8.1  Med: -1.45 Max: 15
Current: -4.5
-8.1
15
EV-to-EBITDA -9.43
AVEO's EV-to-EBITDA is ranked lower than
99.99% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. AVEO: -9.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVEO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.5  Med: -1.50 Max: 14.3
Current: -9.43
-14.5
14.3
Current Ratio 2.82
AVEO's Current Ratio is ranked lower than
66% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. AVEO: 2.82 )
Ranked among companies with meaningful Current Ratio only.
AVEO' s Current Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.40 Max: 9.47
Current: 2.82
1.47
9.47
Quick Ratio 2.82
AVEO's Quick Ratio is ranked lower than
63% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. AVEO: 2.82 )
Ranked among companies with meaningful Quick Ratio only.
AVEO' s Quick Ratio Range Over the Past 10 Years
Min: 1.47  Med: 3.40 Max: 9.47
Current: 2.82
1.47
9.47
Days Sales Outstanding 31.54
AVEO's Days Sales Outstanding is ranked higher than
74% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. AVEO: 31.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
AVEO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.19  Med: 38.64 Max: 390.8
Current: 31.54
3.19
390.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.00
AVEO's Price/Net Cash is ranked lower than
84% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 5.19 vs. AVEO: 20.00 )
Ranked among companies with meaningful Price/Net Cash only.
AVEO' s Price/Net Cash Range Over the Past 10 Years
Min: 1.75  Med: 4.88 Max: 24.76
Current: 20
1.75
24.76
Price/Net Current Asset Value 5.88
AVEO's Price/Net Current Asset Value is ranked lower than
57% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. AVEO: 5.88 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AVEO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.42  Med: 3.45 Max: 19.54
Current: 5.88
1.42
19.54
Price/Tangible Book 5.88
AVEO's Price/Tangible Book is ranked lower than
64% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. AVEO: 5.88 )
Ranked among companies with meaningful Price/Tangible Book only.
AVEO' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.2  Med: 3.01 Max: 14.72
Current: 5.88
1.2
14.72
Price/Median PS Value 0.62
AVEO's Price/Median PS Value is ranked higher than
78% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AVEO: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
AVEO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.22  Med: 1.05 Max: 20.41
Current: 0.62
0.22
20.41
Earnings Yield (Greenblatt) (%) -22.17
AVEO's Earnings Yield (Greenblatt) (%) is ranked lower than
70% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. AVEO: -22.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AVEO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -22.47  Med: 164.40 Max: 48140
Current: -22.17
-22.47
48140

More Statistics

Revenue (TTM) (Mil) $20.09
EPS (TTM) $ -0.20
Beta1.21
Short Percentage of Float0.95%
52-Week Range $0.82 - 2.59
Shares Outstanding (Mil)58.18
» More Articles for NAS:AVEO

Headlines

Articles On GuruFocus.com
Wild Card Wonders, Shopping for 52-Week Lows Sep 28 2013 
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 
Weekly CEO Buys Highlight: AVEO, ZAZA, TUES, TUES, FRAN, AKVA Dec 16 2012 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman’s Baupost Group Q1 Portfolio Update; Buys ANV, SCMR, PDLI, AVEO May 14 2011 
AVEO Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 11 2011 
Two Picks from Seth Klarman: PDLI, AVEO Feb 22 2011 
Hedge Fund Baupost Group buys PDLI, AVEO, ALR, Sells LSTZA, UFS, SLRC, EXXI Feb 11 2011 

More From Other Websites
AVEO Pharmaceuticals (AVEO) Catches Eye: Stock Up 10.4% Jul 22 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : July 19, 2016 Jul 19 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : July 6, 2016 Jul 06 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Jun 15 2016
AVEO to Present at the 2016 JMP Securities Life Science Conference Jun 15 2016
AVEO to Present at the 2016 JMP Securities Life Science Conference Jun 15 2016
Will AVEO Pharmaceuticals (AVEO) Continue to Surge Higher? Jun 08 2016
ETF’s with exposure to AVEO Pharmaceuticals, Inc. : June 3, 2016 Jun 03 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 31 2016
AVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 May 26 2016
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal... May 26 2016
AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal... May 26 2016
AVEO PHARMACEUTICALS INC Financials May 19 2016
Coverage initiated on AVEO Oncology by Piper Jaffray May 19 2016
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and... May 18 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... May 18 2016
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and... May 18 2016
AVEO Announces $17 Million Private Placement May 13 2016
AVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of... May 13 2016
AVEO Announces $17 Million Private Placement May 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)